On July 30, 2026, Catheter Precision, Inc. closed the sale of 2,821 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $2,821,000. The issuance was executed under an Additional Investment Right within a Securities Purchase Agreement dated March 9, 2026, with Dawson James Securities acting as placement agent. Proceeds are designated for working capital, general corporate purposes, and the redemption of outstanding Series B Convertible Preferred Stock. This transaction involves unregistered equity securities exempt from registration under Regulation D and results in dilution to existing common shareholders. Catheter Precision, Inc. operates in the medical device industry, specializing in catheter technologies.
